1. Parkin DM et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
3. Sun CA et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: A prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674-82.
4. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
5. Bruix J. Sherman M, A.A.f.t.S.o.L.D. Practice Guidelines Committee. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018, Jan 4 [Prepub ahead of print, DOI 10.1016/S0140-6736(18)30010-2].
7. Ishizawa T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-16.
8. Poon RT et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol 2001; 19: 3037-44.
9. Morris-Stiff G et al. Surgical management of hepatocellular carcinoma: Is the jury still out? Surg Oncol 2009; 18: 298-321.
10. Portolani N et al. Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
11. Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
12. Rubinstein MM et al. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 2017; 8: 1051-5.
13. Yao FY et al. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-74.
14. Al Sebayel MI et al. Effect of downstaging and bridging of hepatocellular carcinoma on survival following liver transplant: A single center experience. Exp Clin Transplant 2017; 15 (Suppl 2): 7-11.
15. Violi NV et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: A randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol, 2018, Mar 1 [Prepub ahead of print, DOI 10.1016/S2468-1253(18)30029-3].
16. Yu J et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial. Gut 2017; 66: 1172-3.
17. Gao J et al. Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment. World J Gastroenterol 2015; 21: 5287-94.
18. Choi D et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: Long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17: 684-92.
19. Lee DH et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014; 270: 900-9.
20. Tateishi R et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
21. Lee HW et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res 2018; 94: 74-82.
22. Li C and Wen TF. Does surgical resection provide better outcomes than radiofrequency ablation in patients with BCLC very early-stage hepatocellular carcinoma? Ann Surg 2017; 266: e54-e55.
23. Wang JH et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-8.
24. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;. 362: 1907-17.
25. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
26. Lo CM et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
27. Basile A et al. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012; 35: 765-74.
28. Marelli L et al. Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
29. Lewis AL et al. Doxorubicin eluting beads - 1: Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 2007; 18: 1691-9.
30. Camma C et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
31. Chang JM et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994; 74: 2449-53.
32. Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-9.
33. Lammer J et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
34. Sattler T et al. Efficacy and safety of drug eluting bead TACE with microspheres < 150 mum for the treatment of hepatocellular carcinoma. Anticancer Res 2018; 38: 1025-32.
35. Kulik LM et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
36. Abouchaleh N et al. Y90 radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: Long-term outcomes in a 185-patient cohort. J Nucl Med 2017, Dec 7 [Prepub ahead of print, DOI 10.2967/jnumed.117.199752].
37. Sangro B et al. Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations. Am J Clin Oncol 2011; 34: 422-31.
38. Sangro B et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
39. Lau WY et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology 2001; 48: 338-40.
40. Geschwind JF et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S194-205.
41. Salem R et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-39.
42. Kulik LM et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-86.
43. Vilgrain V et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-36.
44. Abou-Alfa GK et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
45. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
46. Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
47. Bruix J et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-54.